Taylor Chen

Gene Therapy Laboratory — France

Biochemistry, Genetics and Molecular Biology · Life Sciences

4h-index513citations11works1.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(3), RNA Interference and Gene Delivery(3), CAR-T cell therapy research(3), Viral Infectious Diseases and Gene Expression in Insects(3), Lymphoma Diagnosis and Treatment(2)

Publications11 total

Preclinical safety and bleeding evaluation in swine for a small interfering RNA-lipid nanoparticle that prevents excess fibrinogen synthesis
Journal of Thrombosis and Haemostasis·2025Open Access
AAVone: A cost-effective, single-plasmid solution for efficient AAV production with reduced DNA impurities
Molecular Therapy — Nucleic Acids·2025· 3 citedOpen Access
AAVone: A Cost-Effective, Single-Plasmid Solution for Efficient AAV Production with Reduced DNA Impurities
2025· 1 citedOpen Access
siRNA-mediated reduction of a circulating protein in swine using lipid nanoparticles
Molecular Therapy — Methods & Clinical Development·2024· 1 citedOpen Access
The Rational Design of Highly Potent and Selective Covalent MAP2K7 Inhibitors
2023Open Access
An Mb1-Cre-driven oncogenic Kras mutation results in a mouse model of T-acute lymphoblastic leukemia/lymphoma with short latency and high penetrance
Leukemia·2020· 4 citedOpen Access
Concise Review: Regulation of Self-Renewal in Normal and Malignant Hematopoietic Stem Cells by Krüppel-Like Factor 4
Stem Cells Translational Medicine·2019· 43 citedOpen Access
Abstract 145: Pharmacologic inhibition of SIAH2 stabilizes DYRK2 and inhibits survival and self-renewal in chronic myeloid leukemia (CML) leukemic stem cells
Cancer Research·2018
Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma
Science Translational Medicine·2015· 448 citedOpen Access
Validation of a humanized anti-EGFR variant III chimeric antigen receptor for a Phase I trial of CART-EGFRvIII in glioblastoma
2015· 1 cited
Novel Chimeric Antigen Receptor T Cells for the Treatment of Hodgkin Lymphoma
Blood·2014· 12 cited

Frequent Co-authors

H. Daniel Lacorazza(4), John Scholler(3), Carl H. June(3), Takayuki Ohkuri(2), Akemi Kosaka(2), Prachi Patel(2), Shannon E. McGettigan(2), Arben Nace(2), Pramod Thekkat(2), Andreas Loew(2), Alina C. Boesteanu(2), Alexandria P. Cogdill(2), Joseph A. Fraietta(2), Christopher C. Kloss(2), Boris Engels(2), Reshma Singh(2), Tucker Ezell(2), Neeraja Idamakanti(2), Melissa Ramones(2), Gabriela Plesa(2)